SHL Telemedicine Ltd. (SHLT) Income Statement Analysis

See more : Far East Hotels and Entertainment Limited (0037.HK) Income Statement Analysis – Financial Results

Complete financial analysis of SHL Telemedicine Ltd. (SHLT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SHL Telemedicine Ltd., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.

You may be interested

Pact Group Holdings Ltd (PCTGY) Income Statement Analysis – Financial Results
Motorcar Parts of America, Inc. (MPAA) Income Statement Analysis – Financial Results
Saxon Capital Group, Inc. (SCGX) Income Statement Analysis – Financial Results
Hyundai Bng Steel Co., Ltd. (004565.KS) Income Statement Analysis – Financial Results
Shenzhen Gongjin Electronics Co., Ltd. (603118.SS) Income Statement Analysis – Financial Results

SHL Telemedicine Ltd. (SHLT)

Industry: Medical - Healthcare Information Services

Sector: Healthcare

Website: https://www.shl-telemedicine.com

About SHL Telemedicine Ltd.

SHL Telemedicine Ltd., together with its subsidiaries, develops and markets personal telemedicine solutions in Israel, Europe, and internationally. The company offers smartheart, a personal mobile 12 lead ECG device that enables the detection of heart attacks; CardioSen'C, a personal cellular-digital 12-lead ECG transmitter device; Cardio'B, a portable device to transmit a 12-lead ECG; and Cardio Beeper 12/12, a hand-held ECG transmitter device for personal use that transmits a full ECG reading to the monitoring center. It also provides central communication module, a telecommunication device that transmits medical data to its telemedicine centers from various medical monitoring devices; TeleWeight, a trans-telephonic weight monitoring device for personal use; TelePress, a remote blood pressure monitoring device for personal use; TeleBreather, a remote electronic handheld device to test the working of lungs; and TelePulse Oximeter, an electronic handheld diagnostic device to measure the saturation level of oxygen in blood, as well as pulse rate. The company offers its telemedicine services and devices to subscribers using telephonic and internet communication technology. It serves patients, health insurance companies, hospitals, clinics, physicians, and other health care providers. The company has a collaboration agreement with Mayo Clinic to evaluate the incidence of emergency department visits, re-hospitalizations, and major adverse cardiovascular events over a period of 90 days after first hospitalization for a heart attack for patients using SmartHeart FDA approved 12 lead ECG; and collaboration agreement with the Hebrew University of Jerusalem and the Hadassah Medical Center to develop an artificial intelligence tool for predicting future life-threatening cardiac events based on 12 Lead ECG monitoring. SHL Telemedicine Ltd. was founded in 1987 and is headquartered in Tel Aviv, Israel.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002
Revenue	57.08M	59.00M	49.58M	40.16M	41.88M	48.86M	37.38M	40.55M	34.58M	39.98M	29.67M	26.94M	42.37M	50.25M	47.89M	44.55M	62.12M	62.85M	99.05M	103.05M	98.78M	89.80M
Cost of Revenue	31.81M	31.81M	24.99M	19.52M	18.42M	18.65M	17.79M	19.48M	20.56M	17.71M	13.73M	12.63M	15.39M	14.69M	13.52M	12.79M	29.57M	30.14M	54.40M	58.40M	52.13M	44.05M
Gross Profit	25.26M	27.19M	24.59M	20.64M	23.46M	30.21M	19.59M	21.07M	14.02M	22.26M	15.94M	14.31M	26.98M	35.56M	34.37M	31.76M	32.55M	32.70M	44.65M	44.65M	46.66M	45.75M
Gross Profit Ratio	44.26%	46.08%	49.60%	51.40%	56.02%	61.83%	52.42%	51.96%	40.55%	55.69%	53.72%	53.10%	63.68%	70.76%	71.77%	71.29%	52.40%	52.04%	45.08%	43.33%	47.23%	50.95%
Research & Development	5.26M	3.79M	-431.00K	-360.00K	2.51M	173.00K	-981.00K	-1.11M	-1.00M	-1.31M	-1.60M	-1.48M	1.33M	1.60M	1.22M	1.00M	2.55M	911.00K	915.00K	712.00K	672.00K	415.00K
General & Administrative	20.36M	20.83M	3.95M	3.93M	2.83M	2.65M	2.54M	4.75M	3.47M	3.00M	2.99M	3.47M	11.91M	10.95M	10.14M	11.53M	14.92M	9.67M	33.97M	32.84M	32.72M	26.68M
Selling & Marketing	3.19M	3.57M	2.81M	1.82M	1.20M	1.05M	1.25M	1.66M	2.46M	2.88M	2.12M	2.01M	9.57M	14.75M	14.04M	12.16M	12.61M	10.91M	13.88M	12.81M	10.20M	7.01M
SG&A	23.55M	24.39M	6.76M	5.75M	4.03M	3.70M	3.79M	6.42M	5.92M	5.88M	5.12M	5.48M	21.48M	25.69M	24.18M	23.69M	27.53M	20.58M	47.85M	45.65M	42.92M	33.68M
Other Expenses	5.45M	-416.00K	-430.00K	-501.00K	-273.00K	633.00K	3.28M	0.00	-2.46M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Expenses	34.27M	31.94M	24.54M	19.70M	17.75M	18.37M	18.31M	22.06M	23.57M	21.12M	21.33M	19.96M	22.81M	27.29M	27.72M	27.52M	42.69M	32.40M	44.18M	46.36M	43.59M	34.10M
Cost & Expenses	66.08M	63.75M	49.53M	39.22M	36.17M	37.02M	36.10M	41.53M	44.13M	38.83M	35.07M	32.59M	38.20M	41.98M	41.24M	40.31M	72.27M	62.54M	98.58M	104.76M	95.71M	78.15M
Interest Income	1.05M	429.00K	376.00K	104.00K	22.00K	134.00K	122.00K	332.00K	126.00K	503.00K	811.00K	824.00K	4.65M	1.32M	1.85M	8.20M	1.41M	601.00K	1.07M	-60.74K	0.00	0.00
Interest Expense	1.56M	1.03M	529.00K	405.00K	292.00K	328.00K	1.12M	2.55M	594.00K	925.00K	1.51M	1.76M	4.03M	1.25M	1.11M	12.61M	6.85M	4.86M	5.66M	4.16M	0.00	0.00
Depreciation & Amortization	7.69M	7.11M	5.39M	4.96M	3.93M	3.97M	4.55M	5.66M	6.34M	6.08M	4.83M	4.27M	4.73M	5.40M	4.78M	7.14M	8.73M	8.65M	4.58M	0.00	0.00	0.00
EBITDA	3.28M	2.14M	-7.25M	5.41M	9.22M	15.95M	8.82M	-520.75K	-8.58M	8.85M	7.87M	-583.76K	10.71M	12.70M	12.95M	11.38M	45.74M	9.71M	469.00K	-1.71M	3.07M	11.66M
EBITDA Ratio	5.75%	3.62%	-14.78%	13.20%	22.05%	33.56%	23.73%	12.19%	-16.69%	20.40%	-1.58%	-2.33%	31.98%	25.27%	27.04%	25.54%	73.44%	15.44%	0.47%	-1.66%	3.11%	12.98%
Operating Income	-9.01M	-5.17M	-497.00K	396.00K	4.77M	11.99M	4.10M	-4.79M	-15.39M	1.29M	3.10M	-5.65M	4.17M	5.98M	6.65M	4.24M	-10.14M	305.00K	-4.12M	-1.71M	3.07M	11.66M
Operating Income Ratio	-15.78%	-8.76%	-1.00%	0.99%	11.39%	24.53%	10.97%	-11.82%	-44.50%	3.22%	10.44%	-20.99%	9.85%	11.91%	13.89%	9.52%	-16.33%	0.49%	-4.15%	-1.66%	3.11%	12.98%
Total Other Income/Expenses	3.04M	6.48M	-12.97M	-319.00K	-309.00K	-522.00K	-1.09M	-2.41M	-383.00K	567.00K	-1.56M	-1.02M	617.00K	68.00K	408.00K	-5.47M	40.29M	-4.10M	3.99M	-6.71M	-10.33M	1.76M
Income Before Tax	-5.96M	1.31M	-13.47M	77.00K	4.77M	11.47M	3.01M	-7.20M	-15.77M	1.85M	1.54M	-6.68M	4.79M	6.05M	7.06M	-1.23M	30.15M	-3.79M	-127.00K	-5.04M	-1.66M	13.42M
Income Before Tax Ratio	-10.45%	2.22%	-27.17%	0.19%	11.39%	23.46%	8.06%	-17.75%	-45.61%	4.64%	5.19%	-24.78%	11.30%	12.04%	14.74%	-2.76%	48.53%	-6.04%	-0.13%	-4.89%	-1.68%	14.94%
Income Tax Expense	891.00K	1.10M	455.00K	-201.00K	-923.00K	1.32M	606.00K	3.90M	863.00K	1.02M	-693.00K	628.00K	792.00K	1.19M	-1.68M	3.46M	6.50M	-412.00K	-7.42M	318.00K	-1.02M	-3.23M
Net Income	-7.06M	-76.00K	-14.11M	278.00K	5.70M	10.14M	2.41M	-11.10M	-16.64M	829.00K	2.23M	-7.30M	4.00M	4.86M	5.38M	2.23M	23.38M	-8.46M	-7.55M	-4.72M	-10.20M	1.41M
Net Income Ratio	-12.36%	-0.13%	-28.46%	0.69%	13.60%	20.75%	6.44%	-27.37%	-48.10%	2.07%	7.52%	-27.11%	9.43%	9.67%	11.23%	5.01%	37.63%	-13.47%	-7.62%	-4.58%	-10.32%	1.57%
EPS	-0.43	-0.01	-1.00	0.03	0.54	0.97	0.23	-1.06	-1.59	0.08	0.22	-0.70	0.38	0.46	0.51	0.21	2.20	-0.80	-0.71	-0.45	-0.96	0.13
EPS Diluted	-0.43	-0.01	-1.00	0.03	0.54	0.96	0.23	-1.06	-1.59	0.08	0.22	-0.69	0.38	0.46	0.51	0.21	2.16	-0.80	-0.71	-0.45	-0.96	0.13
Weighted Avg Shares Out	16.27M	14.54M	14.05M	10.50M	10.50M	10.50M	10.49M	10.49M	10.48M	10.45M	10.37M	10.48M	10.52M	10.52M	10.58M	10.58M	10.62M	10.62M	10.67M	10.57M	10.59M	10.63M
Weighted Avg Shares Out (Dil)	16.27M	14.54M	14.05M	10.50M	10.50M	10.52M	10.50M	10.49M	10.48M	10.56M	10.46M	10.52M	10.52M	10.58M	10.58M	10.58M	10.81M	10.62M	10.67M	10.57M	10.59M	10.63M

SHL Telemedicine Introduces SmartHeart® Direct-to-Consumer Membership Plan in the US

November 27, 2023businesswire.com

TEL AVIV & ZURICH & NEW YORK--(BUSINESS WIRE)---- $SHLT--SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL” or the “Company”), a leading provider and developer of advanced personal telemedicine solutions is pleased to announce the soft launch of the SmartHeart® membership...

SHL Telemedicine Establishes US Nationwide Cardiology Network for ECG Interpretations and Telehealth Visits

November 6, 2023businesswire.com

TEL AVIV, Israel & ZURICH & NEW YORK--(BUSINESS WIRE)---- $SHLT--SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL” or the “Company”), a leading provider and developer of advanced personal telemedicine solutions is pleased to announce the establishment of a comprehensive network...

SHL Telemedicine Announces Advancements in its Direct-to-Consumer Strategy in the US

October 23, 2023businesswire.com

SHL Telemedicine's SmartHeart® Technology Shows Remarkable Effects in Mayo Clinic and Imperial College London Trials

September 26, 2023businesswire.com

TEL AVIV, Israel & ZURICH & NEW YORK--(BUSINESS WIRE)---- $SHLT--SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL” or the “Company”), a leading provider and developer of advanced personal telemedicine solutions, is pleased to announce the initial results from the Mayo...

SHL Announces Half-Year Results 2023 – Strategic Moves to Accelerate Growth

September 21, 2023businesswire.com

TEL AVIV, Israel & ZURICH & NEW YORK--(BUSINESS WIRE)---- $SHLT--Regulatory News: SHL Telemedicine Ltd. (NASDAQ: SHLT; SIX Swiss Exchange: SHLTN) (“SHL” or the “Company”), a leading provider and developer of advanced personal telemedicine solutions, announced today its results for half-year...

SHL Telemedicine's SmartHeart® Technology to Take Center Stage at Upcoming VPM 2023 Conference

September 11, 2023businesswire.com

TEL AVIV, Israel & ZURICH & NEW YORK--(BUSINESS WIRE)---- $SHLT--SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL” or the “Company”), a leading provider and developer of advanced personal telemedicine solutions, is pleased to announce that initial results from trials conducted...